Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
Information source: National Center for Research Resources (NCRR)
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lipodystrophy
Phase: N/A
Status: Completed
Sponsored by: National Center for Research Resources (NCRR) Official(s) and/or principal investigator(s):
Fannie Smith, Study Chair, Affiliation: University of Texas
Summary
OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma
glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic
receptor in 6 patients with regional lipoatrophy and in 6 controls.
II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in
genomic DNA from peripheral blood leukocytes.
Clinical Details
Study design: Screening
Detailed description:
PROTOCOL OUTLINE: Antihypertensives are held, beginning 3 days before the first study day.
An oral challenge is administered as follows: clonidine on day 1, yohimbine on day 2. The
order of administration is reversed in alternate subjects.
Timed measurements of norepinephrine, glycerol, and free fatty acids follow each challenge.
Structural gene sequencing is evaluated for each participant.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Female.
Criteria:
PROTOCOL ENTRY CRITERIA:
- -Disease Characteristics-- Clinical diagnosis of regional lipoatrophy Control subjects:
Women aged 18 to 65 Weight 90% to 150% of ideal No significant acute or chronic illness
- -Patient Characteristics-- Negative pregnancy test required of fertile women
Locations and Contacts
University of Texas Medical Branch, Galveston, Texas 77555-0209, United States
Additional Information
Starting date: November 1999
Last updated: June 23, 2005
|
